N.F.U. MUTUAL UNIT MANAGERS Ltd bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the third quarter, Holdings Channel reports. The fund bought 76,260 shares of the company’s stock, valued at approximately $1,707,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. AlphaGrep UK Ltd bought a new position in shares of Elanco Animal Health in the third quarter valued at approximately $356,000. Benjamin Edwards Inc. grew its stake in Elanco Animal Health by 20.0% during the third quarter. Benjamin Edwards Inc. now owns 32,239 shares of the company’s stock valued at $722,000 after acquiring an additional 5,380 shares in the last quarter. First Trust Advisors LP grew its stake in Elanco Animal Health by 144.3% during the third quarter. First Trust Advisors LP now owns 835,300 shares of the company’s stock valued at $18,702,000 after acquiring an additional 493,382 shares in the last quarter. State Street Corp increased its holdings in Elanco Animal Health by 1.4% during the 3rd quarter. State Street Corp now owns 16,285,257 shares of the company’s stock worth $364,627,000 after acquiring an additional 222,211 shares during the period. Finally, Resona Asset Management Co. Ltd. bought a new stake in Elanco Animal Health during the 3rd quarter worth approximately $35,000. 97.48% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Elanco Animal Health news, insider Timothy Bettington sold 4,350 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the transaction, the insider owned 138,911 shares of the company’s stock, valued at $3,194,953. The trade was a 3.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.14% of the stock is currently owned by corporate insiders.
Top Elanco Animal Health Stories
Here are a few of the latest stories about ELAN:
- Positive Sentiment: Elanco authorized its first share repurchase program, allowing it to buy back up to $600 million of stock—up to 4.5% of shares outstanding. The company cited stronger cash generation, balance-sheet improvement and confidence in continued business momentum. Buybacks can support earnings per share and signal management confidence. Elanco Announces Inaugural $600 Million Share Repurchase Authorization
- Positive Sentiment: Barclays raised its price target to $32 from $30 and maintained an “overweight” rating, signaling a more optimistic view of the shares. Barclays stock recommendations
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Morgan Stanley lowered their target price on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 29th. UBS Group raised their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. The Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research report on Friday, October 16th. They set a “buy” rating and a $32.00 price target for the company. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, Jefferies Financial Group cut shares of Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their price target for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average target price of $30.36.
Read Our Latest Analysis on ELAN
Elanco Animal Health Stock Performance
Shares of ELAN opened at $25.78 on Friday. Elanco Animal Health Incorporated has a 12-month low of $19.40 and a 12-month high of $27.98. The company has a current ratio of 2.09, a quick ratio of 1.07 and a debt-to-equity ratio of 0.55. The company has a market cap of $12.89 billion, a PE ratio of -85.93, a price-to-earnings-growth ratio of 2.18 and a beta of 1.73. The stock has a 50-day moving average price of $23.64 and a 200-day moving average price of $23.92.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.07. The company had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. Elanco Animal Health’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 1.18 earnings per share for the current fiscal year.
Elanco Animal Health announced that its board has initiated a share repurchase program on Thursday, November 19th that authorizes the company to repurchase $600 million in shares. This buyback authorization authorizes the company to repurchase up to 4.5% of its stock through open market purchases. Share buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
About Elanco Animal Health
Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.
Featured Stories
- Five stocks we like better than Elanco Animal Health
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
